Prostate cancer remains one of the most formidable health challenges facing men worldwide, ranking as the second most commonly diagnosed malignancy in the male population. For decades, the cornerstone ...

Men with high-risk prostate cancer have a higher likelihood of residual disease after prostatectomy and may require radiation ...

Prostate cancer can develop without causing noticeable symptoms, particularly in its early stages. Some men may feel ...

Active surveillance is a standard approach for managing men with low‑risk prostate cancer to help delay or avoid treatment, but a significant number of patients eventually experience disease ...

Prostate cancer remains one of the most common malignancies in men worldwide, ranking as the second most prevalent cancer and ...

The statistics are sobering and undeniable — African American men develop prostate cancer at twice the rate of white men and are more likely to die from the disease. This reality makes understanding ...

Learn how prostate cancer is treated at each stage, from active surveillance and surgery to radiation, hormone therapy, and targeted drugs.

Talazoparib plus enzalutamide met the primary endpoint in TALAPRO-2, lowering radiographic progression or death risk by 37% versus enzalutamide, with median rPFS not reached. Efficacy signals extended ...

Prostate cancer screening generally begins around age 50, while men at higher risk may consider starting earlier, closer to ...